Results 131 to 140 of about 68,309 (262)

Safety and Efficacy Findings From a Phase Ib/II Study of ASP‐1929 Photoimmunotherapy With Pembrolizumab in Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma

open access: yesHead &Neck, Volume 48, Issue 1, Page 160-174, January 2026.
ABSTRACT Background ASP‐1929 photoimmunotherapy—cetuximab conjugated to IRDye 700DX and red light (690 nm) for localized drug activation—results in rapid, selective cell killing. Methods This phase Ib/II open‐label study evaluated ASP‐1929 photoimmunotherapy plus pembrolizumab in patients with recurrent/metastatic HNSCC (≥ 1 accessible lesion, PD‐L1 ...
David M. Cognetti   +17 more
wiley   +1 more source

Triage and care for women with symptoms or diagnosis of pregnancy loss between 14 + 0 and 21 + 6 weeks' gestation

open access: yesInternational Journal of Gynecology &Obstetrics, Volume 172, Issue 1, Page 25-50, January 2026.
Abstract Mid‐trimester pregnancy loss (MTL), defined as a pregnancy loss occurring between 14 + 0 and 21 + 6 weeks of gestation, causes significant physical and emotional distress to women and presents clinical challenges to healthcare professionals. It is acknowledged that in low‐resource settings, this guideline might be applicable to births up to 28 
Caroline E. Fox   +46 more
wiley   +1 more source

Ectopic Prostate Tissue in the Bladder Exhibiting Fluorescence on Photodynamic Diagnosis: A Report of Two Cases

open access: yesIJU Case Reports, Volume 9, Issue 1, January 2026.
ABSTRACT Introduction We report two cases of ectopic prostate tissue exhibiting fluorescence during photodynamic diagnosis using 5‐aminolevulinic acid. Case Presentation The first case involved a 57‐year‐old man with a 9‐mm papillary tumor on the right side of the bladder neck.
Michinori Shimizu   +11 more
wiley   +1 more source

Home - About - Disclaimer - Privacy